Discovery and development of anti-angiogenic peptides: A structural link

Ruud P.M. Dings; Irina Nesmelova; Arjan W. Griffioen; Kevin H Mayo

doi:10.1023/B:AGEN.0000011730.94233.06

Discovery and development of anti-angiogenic peptides: A structural link

Ruud P.M. Dings, Irina Nesmelova, Arjan W. Griffioen, Kevin H Mayo

Research output: Contribution to journal › Review article › peer-review

25 Scopus citations

Abstract

Cancer is a disease promoted by excess angiogenesis. Interference with this process poses an attractive approach to controling aberrant tumor growth, a hypothesis first proposed in the early 1970s that led to world-wide focus on identifying and developing angiogenesis inhibitors, which currently number in the hundreds. This review surveys the discovery and development of anti-angiogenic protein fragments and peptides, with a slant towards understanding their structure-function relationships to aid in the design of better therapeutic agents.

Original language	English (US)
Pages (from-to)	83-91
Number of pages	9
Journal	Angiogenesis
Volume	6
Issue number	2
DOIs	https://doi.org/10.1023/B:AGEN.0000011730.94233.06
State	Published - 2003

Bibliographical note

Funding Information:
This research was supported by grants from the Dutch Cancer Society (to A.W. Griffioen), the Department of Defense DA/DAMD 17-99-1-9564 (to K.H. Mayo) and the National Institutes of Health R01 CA-96090 (to K.H. Mayo).

Keywords

Angiogenesis inhibition
Angiostatic peptides
Angiostatic proteins
Designer peptides and review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1023/B:AGEN.0000011730.94233.06

Find It

Find It at U of M Libraries

Cite this

@article{6628a5621fe14163acfb8c7096f0a13e,

title = "Discovery and development of anti-angiogenic peptides: A structural link",

abstract = "Cancer is a disease promoted by excess angiogenesis. Interference with this process poses an attractive approach to controling aberrant tumor growth, a hypothesis first proposed in the early 1970s that led to world-wide focus on identifying and developing angiogenesis inhibitors, which currently number in the hundreds. This review surveys the discovery and development of anti-angiogenic protein fragments and peptides, with a slant towards understanding their structure-function relationships to aid in the design of better therapeutic agents.",

keywords = "Angiogenesis inhibition, Angiostatic peptides, Angiostatic proteins, Designer peptides and review",

author = "Dings, {Ruud P.M.} and Irina Nesmelova and Griffioen, {Arjan W.} and Mayo, {Kevin H}",

note = "Funding Information: This research was supported by grants from the Dutch Cancer Society (to A.W. Griffioen), the Department of Defense DA/DAMD 17-99-1-9564 (to K.H. Mayo) and the National Institutes of Health R01 CA-96090 (to K.H. Mayo).",

year = "2003",

doi = "10.1023/B:AGEN.0000011730.94233.06",

language = "English (US)",

volume = "6",

pages = "83--91",

journal = "Angiogenesis",

issn = "0969-6970",

publisher = "Springer Netherlands",

number = "2",

}

TY - JOUR

T1 - Discovery and development of anti-angiogenic peptides

T2 - A structural link

AU - Dings, Ruud P.M.

AU - Nesmelova, Irina

AU - Griffioen, Arjan W.

AU - Mayo, Kevin H

N1 - Funding Information: This research was supported by grants from the Dutch Cancer Society (to A.W. Griffioen), the Department of Defense DA/DAMD 17-99-1-9564 (to K.H. Mayo) and the National Institutes of Health R01 CA-96090 (to K.H. Mayo).

PY - 2003

Y1 - 2003

N2 - Cancer is a disease promoted by excess angiogenesis. Interference with this process poses an attractive approach to controling aberrant tumor growth, a hypothesis first proposed in the early 1970s that led to world-wide focus on identifying and developing angiogenesis inhibitors, which currently number in the hundreds. This review surveys the discovery and development of anti-angiogenic protein fragments and peptides, with a slant towards understanding their structure-function relationships to aid in the design of better therapeutic agents.

AB - Cancer is a disease promoted by excess angiogenesis. Interference with this process poses an attractive approach to controling aberrant tumor growth, a hypothesis first proposed in the early 1970s that led to world-wide focus on identifying and developing angiogenesis inhibitors, which currently number in the hundreds. This review surveys the discovery and development of anti-angiogenic protein fragments and peptides, with a slant towards understanding their structure-function relationships to aid in the design of better therapeutic agents.

KW - Angiogenesis inhibition

KW - Angiostatic peptides

KW - Angiostatic proteins

KW - Designer peptides and review

UR - http://www.scopus.com/inward/record.url?scp=0842311707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842311707&partnerID=8YFLogxK

U2 - 10.1023/B:AGEN.0000011730.94233.06

DO - 10.1023/B:AGEN.0000011730.94233.06

M3 - Review article

C2 - 14739615

AN - SCOPUS:0842311707

SN - 0969-6970

VL - 6

SP - 83

EP - 91

JO - Angiogenesis

JF - Angiogenesis

IS - 2

ER -

Discovery and development of anti-angiogenic peptides: A structural link

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this